Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)
2019年8月15日 更新者：Merck Sharp & Dohme LLC
A Phase IV, Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Trial and Subsequent Open-Label, Extension Trial to Assess the Safety and Efficacy of Addition of Omarigliptin in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Monotherapy in Addition to Diet and Exercise Therapy
This study will examine the efficacy of omarigliptin 25 mg once weekly compared to placebo in Japanese patients with T2DM who have inadequate glycemic control on insulin monotherapy in addition to diet and exercise therapy.
The primary hypothesis of the study is that omarigliptin 25 mg once weekly provides greater reduction in hemoglobin A1C (HbA1c) compared with placebo as assessed by change from baseline to Week 16 [Phase A (double-blind period)].
調査の概要
詳細な説明
After a screening period of up to 2 weeks followed by a pretreatment period of 2 or 10 weeks, each participant will be receiving assigned double-blind treatment (omarigliptin 25 mg or placebo once weekly) for approximately 16 weeks (Phase A) followed by 36 weeks of open-label treatment (omarigliptin 25 mg once weekly, Phase B).
After the end of treatment each participant will be followed for 21 days.
研究の種類
介入
入学 (実際)
184
段階
- フェーズ 4
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
20年歳以上 (大人、高齢者)
健康ボランティアの受け入れ
いいえ
受講資格のある性別
全て
説明
Inclusion Criteria:
- Have T2DM
Meet all of following criteria at Week -2 of pre-randomization
- On diet and exercise therapy for 6 weeks or longer, AND
- Have been on a stable dosage and administration of insulin (8 to 40 units/day) for 10 weeks or longer, AND.
- Have not been on any additional anti-hyperglycemic agent (AHAs, except for insulin monotherapy) for 8 weeks or longer, AND
- HbA1c ≥7.5% and ≤10.0%
- Fasting Plasma Glucose (FPG) ≥126 mg/dL and ≤230 mg/dL
- Have a body mass index (BMI) >18 kg/m^2 and <40 kg/m^2
- A male or female not of reproductive potential or a female of reproductive potential and agrees to remain abstinent from heterosexual activity, or agrees to use acceptable contraception to prevent pregnancy.
Exclusion Criteria:
- Has type 1 diabetes mellitus or has a history of diabetic ketoacidosis.
Has a history of being administered any of the following AHAs including fixed dose combination (FDC) containing the following ingredients:
- Thiazolidinediones within 12 weeks
- Glucagon-like peptide 1 (GLP-1) receptor agonists within 12 weeks
- Omarigliptin at any time
- Has history of severe hypoglycemia with coma or loss of consciousness, or for whom hypoglycemia was observed greater or equal to two times per week within 8 weeks
- Is currently participating in or has participated in another study with an investigational compound or device within the prior 12 weeks
- Has undergone a surgical procedure within 8 weeks or has planned major surgery during the study.
- Receives a lipid-lowering medication or thyroid replacement therapy at unstable dosage and administration
- Has poorly controlled hypertension
- Has a medical history of active liver disease, including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease.
- Has human immunodeficiency virus (HIV).
- Has had new or worsening signs or symptoms of coronary heart disease or congestive heart failure within the past 3 months, or has acute coronary syndrome, coronary artery intervention, or stroke or transient ischemic neurological disorder within the past 3 months
- Has severe peripheral vascular disease.
- Has a history of malignancy ≤ 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer:
- Has a clinically important hematological disorder.
- (For women of childbearing potential) has a positive urine pregnancy test.
- Is pregnant or breast feeding
- Is expected to conceive during the study
- Is expected to undergo hormonal therapy in preparation to donate eggs during the study
- Routinely consumes >14 alcoholic drinks per week or engages in binge drinking
- Has donated or plans to donate blood products of >300 mL within 8 weeks or during the study
- Has received or plans to receive blood products within 12 weeks or during the study
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Omarigliptin 25 mg
Omarigliptin 25 mg once weekly for 52 weeks (Phase A and B)
|
Omarigliptin, 25 mg orally once weekly
他の名前：
Insulin will be administered subcutaneously during the trial as monotherapy; dosage and administration following each package insert.
|
|
実験的：Placebo→Omarigliptin 25 mg
Placebo to Omarigliptin once weekly for 16 weeks (Phase A) switching to Omarigliptin 25 mg once weekly for 36 weeks (Phase B)
|
Omarigliptin, 25 mg orally once weekly
他の名前：
Insulin will be administered subcutaneously during the trial as monotherapy; dosage and administration following each package insert.
Placebo to omarigliptin orally once weekly
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Constrained Longitudinal Data Analysis of Change From Baseline in Hemoglobin A1c (HbA1c) at Week 16 Excluding Data After Glycemic Rescue (Phase A)
時間枠：Baseline (Day 1) and Week 16
|
HbA1c is a measure of the percentage of glycated hemoglobin in the blood.
Participant whole blood samples were collected at baseline and Week 16 to determine the Constrained Longitudinal Data Analysis least squares mean HbA1c change from baseline (i.e., HbA1c at Week 16 minus HbA1c at baseline).
Participants that met rescue criteria had their insulin dose adjusted as determined clinically appropriate by the investigator to manage glycemic control.
Data after glycemic rescue were excluded from this analysis.
Negative data values indicated a reduction in HbA1c levels.
|
Baseline (Day 1) and Week 16
|
|
Percentage of Participants Who Experienced One or More Adverse Events (AE) Excluding Data After Glycemic Rescue (Phase A)
時間枠：Up to Week 16
|
An adverse event is defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.
Participants that met rescue criteria had their insulin dose adjusted as determined clinically appropriate by the investigator to manage glycemic control.
Data after glycemic rescue were excluded from this analysis.
|
Up to Week 16
|
|
Percentage of Participants Who Experienced One or More AE (Omarigliptin [Phase A+B]; Placebo→Omarigliptin [Phase B Only])
時間枠：Up to Week 52
|
An adverse event is defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.
Participants that met rescue criteria had their insulin dose adjusted as determined clinically appropriate by the investigator to manage glycemic control.
The results for the Placebo→Omarigliptin group summarized data from the open label period only (36 weeks), which corresponds to the study interval in which those participants were exposed to omarigliptin.
|
Up to Week 52
|
|
Percentage of Participants Who Discontinued Study Drug Due to an AE Excluding Data After Glycemic Rescue (Phase A)
時間枠：Up to Week 16
|
An adverse event is defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.
Participants that met rescue criteria had their insulin dose adjusted as determined clinically appropriate by the investigator to manage glycemic control.
Data after glycemic rescue were excluded from this analysis.
|
Up to Week 16
|
|
Percentage of Participants Who Discontinued Study Drug Due to an AE Including Data After Glycemic Rescue (Omarigliptin [Phase A+B]; Placebo→Omarigliptin [Phase B Only])
時間枠：Up to Week 52
|
An adverse event is defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.
Participants that met rescue criteria had their insulin dose adjusted as determined clinically appropriate by the investigator to manage glycemic control.
The results for the Placebo→Omarigliptin group summarized data from the open label period only (36 weeks), which corresponds to the study interval in which those participants were exposed to omarigliptin.
|
Up to Week 52
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Constrained Longitudinal Data Analysis of Change From Baseline in Fasting Plasma Glucose (FPG) at Week 16 Excluding Data After Glycemic Rescue (Phase A)
時間枠：Baseline (Day 1) and Week 16
|
Blood glucose was measured on a fasting basis.
FPG is expressed as mg/dL.
Blood was drawn at predose on Day 1 and after 16 weeks of treatment to determine Constrained Longitudinal Data Analysis change in plasma glucose levels (i.e., FPG at Week 16 minus FPG at baseline).
Participants that met rescue criteria had their insulin dose adjusted as determined clinically appropriate by the investigator to manage glycemic control.
Data after glycemic rescue were excluded from this analysis.
Negative data values indicated a reduction in FPG levels.
|
Baseline (Day 1) and Week 16
|
|
Percentage of Participants Achieving Hemoglobin A1c Goals (<7.0%) at Week 16 Constrained Longitudinal Data Analysis Using Multiple Imputation Excluding Data After Glycemic Rescue (Phase A)
時間枠：Week 16
|
HbA1c is a measure of the percentage of glycated hemoglobin in the blood.
Participants that met rescue criteria had their insulin dose adjusted as determined clinically appropriate by the investigator to manage glycemic control.
Data after glycemic rescue were excluded from this analysis.
Each of the 10 imputed data sets was summarized to obtain the percentage of responders within each group and were combined using standard multiple imputation techniques to yield an overall estimate of response rate and associated variance for each group.
A constrained longitudinal data analysis was used to analyze the data and Wilson score method by treatment groups used for the analysis of percentages of individuals at the HbA1c goals of <7.0% at Week 16 and the 95% confidence intervals (CIs).
Miettinen & Nurminen (M&N) method after imputations were used to calculate the treatment differences of the percentages of individuals and the 95% CIs.
|
Week 16
|
|
Percentage of Participants Achieving HbA1c Goals (<6.5%) at Week 16 Constrained Longitudinal Data Analysis Using Multiple Imputation Excluding Data After Glycemic Rescue (Phase A)
時間枠：Week 16
|
HbA1c is a measure of the percentage of glycated hemoglobin in the blood.
Participants that met rescue criteria had their insulin dose adjusted as determined clinically appropriate by the investigator to manage glycemic control.
Data after glycemic rescue were excluded from this analysis.
Each of the 10 imputed data sets was summarized to obtain the percentage of responders within each group and were combined using standard multiple imputation techniques to yield an overall estimate of response rate and associated variance for each group.
A constrained longitudinal data analysis was used to analyze the data and Wilson score method by treatment groups used for the analysis of percentages of individuals at the HbA1c goals of <6.5% at Week 16 and the 95% confidence intervals (CIs).
Miettinen & Nurminen (M&N) method after imputations were used to calculate the treatment differences of the percentages of individuals and the 95% CIs.
|
Week 16
|
|
Constrained Longitudinal Data Analysis of Change From Baseline in 1,5-anhydroglucitol (1,5-AG) at Week 16 Excluding Data After Glycemic Rescue (Phase A)
時間枠：Baseline (Day 1) and Week 16
|
1,5-anhydroglucitol (1,5-AG) is a marker of short-term glycemic control especially postprandial hyperglycemia.
1,5-AG accurately predicts rapid changes in glycemia and is tightly associated with glucose fluctuations and postprandial glucose.
Participants that met rescue criteria had their insulin dose adjusted as determined clinically appropriate by the investigator to manage glycemic control.
Data after glycemic rescue were excluded from this analysis.
Data (1,5-AG at Week 16 minus 1,5-AG at baseline) was analyzed by Constrained Longitudinal Data Analysis.
Positive data values indicate an increase in 1,5-AG levels and correlate with an improvement in glycemia.
|
Baseline (Day 1) and Week 16
|
|
Change From Baseline in Hemoglobin A1c (HbA1c) at Week 52 (Phase A+B)
時間枠：Baseline (Day 1) and Week 52
|
HbA1c is a measure of the percentage of glycated hemoglobin in the blood.
Participant whole blood samples were collected at baseline and Week 52 to determine the mean HbA1c change from baseline (i.e., HbA1c at Week 52 minus HbA1c at baseline).
Participants that met rescue criteria had their insulin dose adjusted as determined clinically appropriate by the investigator to manage glycemic control.
Negative data values indicated a reduction in HbA1c levels.
|
Baseline (Day 1) and Week 52
|
|
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52 (Phase A+B)
時間枠：Baseline (Day 1) and Week 52
|
Blood glucose was measured on a fasting basis.
FPG is expressed as mg/dL.
Blood was drawn at predose on Day 1 and after 52 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 52 minus FPG at baseline).
Participants that met rescue criteria had their insulin dose adjusted as determined clinically appropriate by the investigator to manage glycemic control.
Negative data values indicated a reduction in FPG levels.
|
Baseline (Day 1) and Week 52
|
|
Percentage of Participants Achieving Hemoglobin A1c Goals (<7.0%) at Week 52 (Phase A+B)
時間枠：Week 52
|
HbA1c is a measure of the percentage of glycated hemoglobin in the blood.
Participants that met rescue criteria had their insulin dose adjusted as determined clinically appropriate by the investigator to manage glycemic control.
For the HbA1c goals of <7.0% at Week 52, the percentage of participants and the 95% confidence intervals were calculated using Wilson score method by treatment groups of the double-blind period.
|
Week 52
|
|
Percentage of Participants Achieving Hemoglobin A1c Goals (<6.5%) at Week 52 (Phase A+B)
時間枠：Week 52
|
HbA1c is a measure of the percentage of glycated hemoglobin in the blood.
Participants that met rescue criteria had their insulin dose adjusted as determined clinically appropriate by the investigator to manage glycemic control.
For the HbA1c goals of <6.5% at Week 52, the percentage of participants and the 95% confidence intervals were calculated using Wilson score method by treatment groups of the double-blind period.
|
Week 52
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
スポンサー
出版物と役立つリンク
研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (実際)
2016年10月17日
一次修了 (実際)
2018年8月21日
研究の完了 (実際)
2018年8月21日
試験登録日
最初に提出
2016年9月15日
QC基準を満たした最初の提出物
2016年9月15日
最初の投稿 (見積もり)
2016年9月20日
学習記録の更新
投稿された最後の更新 (実際)
2019年9月19日
QC基準を満たした最後の更新が送信されました
2019年8月15日
最終確認日
2019年8月1日
詳しくは
本研究に関する用語
その他の研究ID番号
- 3102-039
- MK-3102-039 (その他の識別子：Merck Protocol Number)
- 163455 (レジストリ識別子：JAPIC-CTI)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
はい
IPD プランの説明
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。